IP Library Granted Patent US 11,396,668
Granted Patent B2
US 11,396,668 · App. 16/918,529 · Granted Jul 26, 2022

Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids

Inventors: Christina D. Smolke (Menlo Park, CA); Catherine Thodey (Mountain View, CA); Isis Trenchard (Redwood City, CA)
Assignee: Antheia, Inc.
C12P17/182C12N9/0006C12N9/0028C12N9/0071C12N9/14C12N9/90C12N15/85C12P17/12C12P17/18C12Y105/01027C12Y114/16002C12Y114/21004C12N2015/8518C12Y305/04016
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,396,668
App. No.
16/918,529
Granted
Jul 26, 2022
Kind
B2
Abstract

A method of demethylizing an opioid to a nor-opioid is provided. The method comprises contacting an opioid with at least one enzyme. Contacting the opioid with the at least one enzyme converts the opioid to a nor-opioid. A method of converting a nor-opioid to a nal-opioid is provided. The method comprises contacting a nor-opioid with at least one enzyme. Contacting the nor-opioid with the at least one enzyme converts the nor-opioid to a nal-opioid.

Claims (10)

1. A method of demethylating an opioid to a nor-opioid, comprising:

contacting a first opioid with at least one enzyme within an engineered non-plant cell, wherein contacting the first opioid with the at least one enzyme converts the first opioid to a second opioid through loss of an O-linked methyl group; and

contacting the second opioid with at least one enzyme within the engineered non-plant cell, wherein contacting the opioid with the at least one enzyme converts the second opioid to a nor-opioid through loss of an N-linked methyl group.

2. The method of claim 1 , wherein the nor-opioid is produced by culturing the engineered non-plant cell comprising a coding sequence for encoding the first enzyme.

3. The method of claim 2 , further comprising:

recovering the nor-opioid from the cell culture.

4. The method of claim 2 , wherein the nor-opioid is produced within the engineered non-plant cell by a metabolic pathway starting with L-tyrosine.

5. The method of claim 2 , wherein the engineered non-plant cell is an engineered bacterial cell.

6. The method of claim 2 , wherein the engineered non-plant cell is an engineered yeast cell.

7. The method of claim 1 , wherein the loss of the O-linked methyl group occurs at the 3′ position.

Assignments (2)
SECURITY INTEREST Recorded Aug 29, 2025
From: ANTHEIA, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 072750/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2020
From: SMOLKE, CHRISTINA D.; THODEY, CATHERINE; TRENCHARD, ISIS
To: ANTHEIA, INC.
Reel/Frame 053464/0294 →
Continuity (5)
Continuation 16127084 · Sep 10, 2018
Continuation PCTUS2017057237 · Oct 18, 2017
Provisional Application 62409837 · Oct 18, 2016
Provisional Application 62473215 · Mar 17, 2017
Related Publication 20210087596A1 · Mar 25, 2021